Ozmosi | Sarcolysin Drug Profile

Product Description

St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Russia

Approved Indications: None

Known Adverse Events: None

Company: City of Hope Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ACTRN12622000300774p	2006-7041-83/hah	N/A	Not yet recruiting	Chronic Cough	2023-10-31
NCT01769911	NCI-2012-03168	N/A	Withdrawn	AIDS-Related Lymphoma\|Diffuse Large B-Cell Lymphoma\|Large-Cell Immunoblastic Lymphoma\|Extranodal NK-T-Cell Lymphoma\|Hairy Cell Leukemia\|Burkitt Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Mantle-Cell Lymphoma\|Waldenstrom Macroglobulinemia\|Sezary Syndrome\|Immunoblastic Lymphadenopathy\|T-Cell Peripheral Lymphoma\|Adult T-Cell Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin\|B-Cell Marginal Zone Lymphoma\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Large-Cell Anaplastic Lymphoma\|Lymphomatoid Granulomatosis\|Plasmablastic Lymphoma\|T-Cell Cutaneous Lymphoma\|Follicular Lymphoma\|Leukemia, Plasma Cell\|Intraocular Lymphoma\|Large Granular Lymphocytic Leukemia\|Mycosis Fungoides\|Chronic Lymphoid Leukemia	2019-02-01	2024-11-27	Primary Endpoints
NCT02960646	NCI-2016-01915	P1	Completed	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Myeloid Leukemia\|Lymphoma, Non-Hodgkin\|Multiple Myeloma\|Acute Lymphoid Leukemia\|Blast Crisis\|Chronic Lymphoid Leukemia\|Acute Monocytic Leukemia\|Leukemia, Plasma Cell\|Chronic Myeloid Leukemia\|Preleukemia\|Anemia, Aplastic\|Lymphocytic Chronic B-Cell Leukemia\|Chronic Myelomonocytic Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Lymphoma, B-Cell\|Myeloproliferative Disorders\|Juvenile Myelomonocytic Leukemia,\|Acute Myelomonocytic Leukemia	2023-02-13	2023-02-18	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT01619761	NCI-2012-02071	P1	Unknown status	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Myeloid, Accelerated Leukemia\|Myelodysplastic Syndrome\|Leukemia, Plasma Cell\|Lymphoma, B-Cell\|Multiple Myeloma\|Chronic Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Preleukemia\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Biphenotypic Acute Leukemia\|Lymphoma, Non-Hodgkin	2021-11-01	2022-02-02	Primary Endpoints\|Treatments\|Trial Status
NCT01625351	RADIANT	P1	Completed	Sarcoma, Ewing\|Adenomyoepithelioma\|Gastrointestinal Cancer\|Rhabdomyosarcoma\|Clear Cell Sarcoma\|Lymphoma\|Renal Cell Carcinoma\|Wilms Tumor\|Rhabdoid Tumor\|Melanoma\|Neuroblastoma\|Clear Cell Adenocarcinoma	2020-02-10	2020-10-20	Primary Endpoints
NCT02130869	ASCIST	P1	Completed	Lymphoma\|Neuroblastoma	2017-12-20	2024-11-27	Primary Endpoints
NCT02472392	Ewing/Allo	P1	Completed	Sarcoma, Ewing	2016-12-01	2019-03-20	Treatments
NCT05031897	21D.466	P2	Recruiting	Chronic Myeloid Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Multiple Myeloma\|Myelofibrosis\|Acute Monocytic Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Anemia, Aplastic\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Adult T-Cell Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin\|Chronic Myelomonocytic Leukemia\|Acute Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Polycythemia Vera\|Lymphoma, B-Cell\|Lymphocytic Chronic B-Cell Leukemia\|Chronic Lymphoid Leukemia\|Thrombocythemia, Essential	2032-04-01	2025-10-31	Primary Endpoints
NCT05564390	MYELOMATCH	P2	Recruiting	Myelodysplastic Syndrome\|Acute Myeloid Leukemia	2029-05-15	2026-01-13
NCT02727803	NCI-2016-00584	P2	Recruiting	Myeloproliferative Disorders\|Preleukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Myelodysplastic-Myeloproliferative Diseases\|Chronic Lymphoid Leukemia\|Lymphoma, B-Cell\|Chronic Myeloid Leukemia\|Leukemia, Plasma Cell\|Acute Lymphoid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Acute Myeloid Leukemia\|Myeloid, Accelerated Leukemia\|Chronic Myelomonocytic Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Myelomonocytic Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Anemia, Refractory, with Excess of Blasts\|B-Cell Leukemia\|Multiple Myeloma\|Acute Monocytic Leukemia\|Lymphoma, Non-Hodgkin\|Biphenotypic Acute Leukemia\|Myelodysplastic Syndrome	2027-05-31	2025-05-10	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT00692939	STUDY19100005	P2	Recruiting	Crohn Disease	2026-12-01	2025-12-16	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT02700841	0669-19-FB	P2	Terminated	Multiple Myeloma	2022-12-21	2023-08-30	Primary Endpoints\|Start Date\|Treatments
NCT03096782	NCI-2018-01236	P2	Completed	Preleukemia\|Myeloid, Accelerated Leukemia\|Acute Myeloid Leukemia\|Acute Myelomonocytic Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Juvenile Myelomonocytic Leukemia,\|Anemia, Refractory, with Excess of Blasts\|Myelodysplastic Syndrome\|Lymphoma, Non-Hodgkin\|Acute Monocytic Leukemia\|Acute Lymphoid Leukemia\|Chronic Myeloid Leukemia\|Hodgkin Lymphoma\|Lymphoma, B-Cell\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Biphenotypic Acute Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Myelomonocytic Leukemia\|Chronic Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Histiocytosis, Langerhans-Cell	2022-09-20	2023-06-30	Primary Endpoints
NCT01904136	NCI-2013-02183	P2	Completed	Blast Crisis\|Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Myeloid, Accelerated Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Myeloid Leukemia\|Preleukemia	2022-02-28	2024-01-18
NCT01857934	Neuroblastoma Protocol 2012	P2	Active, not recruiting	Neuroblastoma	2021-10-21	2024-11-27	Primary Endpoints\|Treatments
NCT01807611	HAPNK1	P2	Completed	Leukemia\|Lymphoma	2021-08-27	2022-11-01	Patient Enrollment\|Primary Endpoints\|Treatments
NCT02797470	AMC-097	P2	Active, not recruiting	Large-Cell Immunoblastic Lymphoma\|Lymphoma, Non-Hodgkin\|Follicular Lymphoma\|Mantle-Cell Lymphoma\|T-Cell Lymphoma\|Burkitt Lymphoma\|Plasmablastic Lymphoma\|HIV Infections	2021-05-13	2024-11-27	Primary Endpoints\|Treatments
NCT04205240	OSU-19190	P2	Terminated	Multiple Myeloma	2021-05-08	2023-09-29	Primary Endpoints
NCT02756572	NCI-2016-00477	P2	Completed	Preleukemia\|Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Monocytic Leukemia\|Acute Myelomonocytic Leukemia\|Chronic Myelomonocytic Leukemia\|Juvenile Myelomonocytic Leukemia,\|Anemia, Refractory, with Excess of Blasts	2020-03-01	2024-11-27	Primary Endpoints\|Treatments
NCT01008462	NCI-2009-01334	P2	Completed	Chronic Lymphoid Leukemia\|Prolymphocytic B-Cell Leukemia\|T-Cell Lymphoma\|Leukemia, Plasma Cell\|Multiple Myeloma\|Lymphocytic Chronic B-Cell Leukemia\|Lymphoma, B-Cell\|Prolymphocytic Leukemia\|Lymphoma, Non-Hodgkin\|Waldenstrom Macroglobulinemia\|Prolymphocytic T-Cell Leukemia	2018-06-30	2024-11-27	Primary Endpoints
NCT01531244	11-X335	P2	Withdrawn	Melanoma	2016-02-01	2024-06-26	Primary Endpoints
NCT02259348	REFNK1	P2	Terminated	Acute Myeloid Leukemia\|Acute Lymphoid Leukemia\|Lymphoma, Non-Hodgkin\|Juvenile Myelomonocytic Leukemia,\|Myelodysplastic Syndrome\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Lymphoid Leukemia\|Acute Monocytic Leukemia\|Chronic Myelomonocytic Leukemia\|Preleukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Sarcoma, Myeloid\|Acute Myelomonocytic Leukemia\|Chronic Myeloid Leukemia	2015-04-01	2019-03-20
NCT06172296	NCI-2023-08530	P3	Recruiting	Ganglioneuroblastoma	2029-12-31	2025-08-27	Primary Endpoints\|Treatments
NCT05457556	ASCT2031	P3	Active, not recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|Myelodysplastic Syndrome\|Preleukemia\|Acute Myeloid Leukemia	2026-06-30	2025-05-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT00567567	ANBL0532	P3	Completed	Neuroblastoma	2015-02-27	2024-11-27	Primary Endpoints

Recent News Events

Date	Type	Title
05/15/2024	PubMed	Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
05/10/2024	PubMed	Current status of bispecific antibodies and CAR-T therapies in multiple myeloma.
04/27/2024	PubMed	Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Sarcolysin

Alternative Names: sarcolysin Clinical Status: Inactive Latest Update: 2026-01-12 Latest Update Note: Clinical Trial Update